Recursive partitioning analysis of 1592 patients on four radiation therapy oncology group studies in inoperable non-small cell lung cancer

Lung Cancer

Volumn 17, Issue SUPPL. 1, 1997, Pages

  Scott, Charles ^a   Sauce, William T ^b   Byhardt, Roger ^c   Marcial, Victor ^d   Pajak, F ^a   Herskovic, Arnold ^e   Cox, James D ^f  

^a RADIATION THERAPY ONCOLOGY GROUP   (United States)

^b LDS HOSPITAL   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Radiation Oncology Center   (Puerto Rico)

^e OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Non small cell lung; Recursive partitioning

Indexed keywords

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOTHERAPY;

AGED; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE;

EID: 0030928296     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00640-5     Document Type: Conference Paper

References (19)

1. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(Suppl): 225-233.
2. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8: 1543-1555.
3. Asbell SO, Pajak T, Seydel HG, Brady L, Mohuiddin M, Weigensberg I, Montesano AT. Phase III RTOG double blind lung cancer trial of XRT and subsequent thymosin or placebo. Proc Am Soc Clin Oncol 1990; 8: 242.
4. Russell AH, Pajak TE, Selim HM, Paradelo JC, Murray K, Bansal P, Cooper JD, Silverman S, Clement JA. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991; 21: 637-643.
5. Byhardt RW, Pajak TF, Emami B, Herskovic A, Doggett RS, Olsen LA. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys 1993; 26: 459-468.
6. Ciampi A, Triffault J. Recursive partition and amalgamation (RECPAM) for censored survival data: criteria for tree selection. Stat Soft News 1988; 14: 78-81.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am StatAssoc 1958; 53: 457-481.
8. Prentice RL, Marek P. A qualified discrepancy between censored data rank tests. Biometrics 1979; 35: 861-867.
9. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonneferoni test. Biometrika 1988; 75: 383-386.
10. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-229.
11. Korn EL, Simon R. Measures of explained variation for survival data. Stat Med 1990; 9: 487-503.
12. Sause WT, Scott C, Taylor S, Byhardt RW, Banker FL, Thomson JW, Jones TK, Cooper JS, Lindberg RD. Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer. Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 1992; 15: 163-167.
13. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, Dar AR, Cox JD. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
14. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RLS, Coughlin C, Scarantino C, Rotman M, Emami B. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer: results of Radiation Therapy Oncology Group 90-15. Cancer 1995; 75: 2337-2339
15. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW and Curran WJ. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: RTOG Protocol 91-06. J Clin Oncol 1996; 14: 1055-1064.
16. Asamura H, Naruke T. Lung carcinoma. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, editors. Prognostic Factors in Cancer. Berlin: Springer-Verlag, 1995: 118-129.
17. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group Experience. J Clin Oncol 1991; 9: 1618-1626.
18. Sagman U, Maki E. Evans WK, Warr D, Shepherd PA, Sculier JP, Haddad R, Payne D, Pringle JF, Yeah JL, Ciampi A, DeBoer G, McKinney S, Ginsberg R, Feld R. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 1991; 9: 1639-1649.
19. Hermanek P, Sobin LH, Fleming ID. What do we need beyond TNM? Cancer 1996; 77: 815-817.